RADIANCE Blend (GHK-Cu / Tesamorelin): What It Is, Where to Get It Prescribed, and What It Costs

RADIANCE is not a single molecule. It is two independently studied peptides — GHK-Cu and tesamorelin — dissolved together in one sterile multi-dose vial by a compounding pharmacy. The two could hardly be more different in where their evidence comes from. GHK-Cu is a naturally occurring tripeptide with a large cell and animal literature and human studies that are almost all topical. Tesamorelin is the active ingredient of an FDA-approved prescription biologic, with randomised, placebo-controlled human trials behind it. The name RADIANCE is a brand name for the combination; it does not appear in any journal. So "does RADIANCE work" has to be broken into two questions, because the combination itself has never been studied as a combination.

The rationale prescribers give is that skin and tissue quality has two inputs that decline together with age: the local matrix — collagen, elastin, the proteins between cells — and the growth-hormone / IGF-1 axis that governs how quickly tissue is turned over and how body fat is distributed. GHK-Cu is described in the research as acting on the first; tesamorelin acts on the second. One vial covers both with a single injection.

The proportions are worth noticing. GHK-Cu is 50 of the 60 mg in the vial, so by mass RADIANCE is mostly a GHK-Cu preparation with a smaller tesamorelin component: 2.5 mg GHK-Cu and 0.5 mg tesamorelin per standard 0.25 mL dose. The ratio is fixed by the pharmacy's formulation and cannot be adjusted per component, which is the genuine trade-off of any blend.

It is not a weight-loss medication. Tesamorelin's own approved label states that it is not indicated for weight-loss management because its effect on body weight is neutral; the trials measured visceral fat, not the scale. It is not a cosmetic filler, a retinoid or a substitute for sun protection, and nothing on this page describes it changing what you see in the mirror. It is not injected growth hormone: tesamorelin prompts your own pituitary rather than replacing its output. And it is not a shortcut around the slow biology of skin.

GHK-Cu is a tripeptide — glycine, histidine, lysine — that binds copper with high affinity. It occurs naturally in human plasma, where its concentration is reported to decline with age. The copper-carrying role is the basis for most of its described effects, because collagen cross-linking, elastin formation and several antioxidant enzymes are copper-dependent.

In cell and animal work, and in reviews in Biomed Research International (2015) and the International Journal of Molecular Sciences (2018), GHK-Cu is described as increasing synthesis of collagen, elastin, proteoglycans and glycosaminoglycans, and as shifting the balance between matrix metalloproteinases, which break tissue down, and their inhibitors. Gene-expression work reports effects across a large number of genes rather than one pathway, which is why the literature discusses it as resetting tissue toward a repair pattern. The rat wound work behind these claims used the peptide injected locally into experimental wounds; none of it used the systemic subcutaneous route.

The human GHK-Cu literature is almost entirely topical. A 1994 study in Wound Repair and Regeneration applied a GHK-Cu gel to diabetic foot ulcers and reported faster closure than the comparison dressing. A 2006 study in Archives of Facial Plastic Surgery applied a copper-tripeptide cream after CO2 laser resurfacing of facial skin and reported on re-epithelialisation. The cosmetic studies of GHK-Cu creams in photoaged skin, summarised in the 2015 review, measured firmness, fine lines and elasticity in small groups.

The precision that matters: those studies describe what a cream or gel did on the skin it was applied to. They do not describe what an injection into the abdomen does to the face, and no study has tested that. The injectable form's evidence is the cell and animal work above plus clinical prescribing experience. Citing the topical human studies as evidence for the injection is mixing two different things.

Tesamorelin is a 44-amino-acid synthetic analogue of human growth-hormone-releasing hormone, modified at the N-terminus to resist breakdown by the enzyme DPP-4. It binds the GHRH receptor on the pituitary and prompts a pulse of the body's own growth hormone, which in turn raises IGF-1, the hormone the liver makes in response. Because it works through the pituitary, the response stays under the body's own feedback control: somatostatin still puts the brakes on, and release stays pulsatile rather than flat. That is the distinction between a secretagogue like tesamorelin and injected growth hormone. The pharmacology here is human, established during development of the approved product.

Growth hormone promotes the breakdown of stored fat, and visceral fat — the fat packed around the organs inside the abdomen, as opposed to the fat under the skin — is particularly responsive to it. That is why the approved indication concerns visceral adipose tissue specifically, and why trials measured it with CT scans rather than scales. The New England Journal of Medicine (2007) trial and the pooled analysis in the Journal of Clinical Endocrinology & Metabolism (2010) reported visceral fat falling on tesamorelin against a small rise on placebo, with IGF-1 rising and body weight essentially unchanged. Skin was not an endpoint in any tesamorelin trial.

The map below is the clinical rationale for the blend. It is a rationale, not a finding — no study has confirmed that the two act together when injected together.

This rests on GHK-Cu. The cell and animal literature is deep and coherent: more collagen and matrix laid down, a shift away from matrix breakdown, effects on a large number of genes. The human literature is topical, small, and concerned with wound closure and cosmetic measures of photoaged skin. There are no human studies of injectable GHK-Cu for skin quality. Hair is similar: the basis is laboratory work on hair follicles and animal studies, and there is no human trial of GHK-Cu, topical or injectable, with hair growth as an endpoint. The fuller treatment is on the GHK-Cu page.

This rests on tesamorelin and it is the strongest evidence on this page. Two phase 3 randomised, double-blind, placebo-controlled trials in people with HIV and abdominal fat accumulation, published in the New England Journal of Medicine (2007) and the Journal of Acquired Immune Deficiency Syndromes (2010) and pooled in the Journal of Clinical Endocrinology & Metabolism (2010), reported reduced visceral adipose tissue on CT at 26 weeks, lower triglycerides and a rise in IGF-1, with body weight neutral. A randomised trial in the Journal of Clinical Endocrinology & Metabolism (2012) in abdominally obese adults without HIV who had reduced growth hormone secretion reported reduced visceral fat over 12 months. A randomised, double-blind trial in Lancet HIV (2019) in people with HIV and non-alcoholic fatty liver disease reported a reduction in liver fat fraction over 12 months. Every one of these used the approved product at 1 mg or 2 mg once daily, every day.

This is the honest part, and it is the part worth understanding before starting.

There are no randomised controlled trials of RADIANCE, or of any GHK-Cu and tesamorelin combination, in humans. The blend has never been studied as a blend. Evidence is per component, and it is very uneven:

• GHK-Cu has small human studies of topical creams and gels — for diabetic ulcers, post-laser skin and photoaged facial skin. There are no randomised controlled trials of injectable GHK-Cu in humans for any indication.
• Tesamorelin has randomised, double-blind, placebo-controlled trials, including the two phase 3 trials that supported an FDA approval, with roughly 1,100 people randomised across the published trials. Almost all were in people with HIV, every trial used a fixed daily dose of 1 mg or 2 mg, and the endpoints were visceral fat, liver fat and metabolic markers — not skin, not hair.

Two gaps are specific to RADIANCE. The tesamorelin in a standard injection is 0.5 mg, five days a week; the trials used 1 to 2 mg every day, so the blend delivers a fraction of the studied exposure and nobody has measured what that fraction does. And none of the tesamorelin trials looked at skin, so the skin rationale rests entirely on GHK-Cu's preclinical and topical literature plus prescriber experience.

Much of medicine rests on mechanism plus clinical experience, and that is the basis on which physicians prescribe RADIANCE. But the accurate framing is "one component described in preclinical research and used clinically, one component with human trials at a different dose for a different endpoint," not "proven in people."

• That the two peptides together do more than either alone. No study has compared the blend with its components.
• Any effect of the blend, or of either component, on the appearance of skin, on wrinkles, on hair growth or on complexion in humans. No such trial has been run.
• An effect of RADIANCE on visceral fat. That data belongs to the approved tesamorelin product at 1 to 2 mg daily, not to 0.5 mg five days a week in a blend.
• An effect on body weight. Tesamorelin's own label describes its effect on weight as neutral.
• A timeline in humans. Timelines given by prescribers are clinical experience, not trial endpoints.
• Long-term safety of the combination over years, which is part of why a physician reviews each refill and why bloodwork is commonly required.
• Efficacy for any condition as an FDA-approved treatment. RADIANCE is not approved for anything; the approved tesamorelin product is approved for one indication that RADIANCE is not prescribed for.

In 2023 the FDA placed injectable GHK-Cu in Category 2 of its interim 503A bulk drug substances list — the category for nominated substances flagged as raising significant safety risks — citing a possible immunogenicity risk from aggregation and peptide-related impurities and limited human safety data. Non-injectable GHK-Cu sat separately in Category 1, the list of substances under evaluation.

On 15 April 2026 the FDA announced the removal of twelve peptides from Category 2, and injectable GHK-Cu was one of them. The FDA's current 503A category list, updated 14 May 2026, no longer lists GHK-Cu in Category 2 at all; Category 2 is now six substances, none of them in RADIANCE. The same document records that non-injectable GHK-Cu was removed from Category 1 on 22 April 2026 after its nominators withdrew, that one nominator clarified on 5 May 2026 it meant to withdraw only the injectable route, and that non-injectable GHK-Cu will be added back to Category 1. It also states that the FDA intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 on whether GHK-Cu should be added to the 503A Bulks List.

GHK-Cu was not on the committee's 23–24 July 2026 agenda, which covered BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax and epitalon. So the accurate description today is: no longer flagged, not yet on the positive list, with a formal advisory-committee review scheduled.

Tesamorelin did not move in the 2026 changes because it was never on the 503A category list. That list is for substances nominated for compounding that are not components of approved drugs, and tesamorelin is the active ingredient of one.

Egrifta (tesamorelin acetate) was approved on 10 November 2010, application 022505, for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. On 23 March 2020 that approval was deemed a biologics licence under the Public Health Service Act, in the transition that moved protein products onto the FDA's Purple Book. Two formulations are current: Egrifta SV, dosed at 1.4 mg once daily from a 2 mg vial, and Egrifta WR, approved on 25 March 2025, dosed at 1.28 mg once daily from an 11.6 mg vial reconstituted for a week's use. Both labels carry the same limitations of use: long-term cardiovascular safety has not been established, the product is not indicated for weight-loss management because its effect on weight is neutral, and there is no evidence it improves antiretroviral adherence. Both are contraindicated in disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity, and pregnancy.

The tesamorelin in RADIANCE is prepared by a state-licensed pharmacy to an individual physician's prescription. It has not been reviewed by the FDA for safety, effectiveness or manufacturing quality as a finished product, and the trial data above belongs to the approved product at its approved doses. Prescribing tesamorelin for anything other than HIV-associated lipodystrophy is off-label, which is a physician's decision and common across medicine, but it should be understood as such.

Neither component is restricted. GHK-Cu is off the safety-risk list and scheduled for advisory-committee review; tesamorelin is an approved active whose approved product is licensed for a different indication than RADIANCE is used for. RADIANCE itself is not an FDA-approved drug product, and compounded medications never are — they are prepared by a licensed pharmacy to a physician's prescription, not approved as manufactured products.

Most people notice little or nothing. Injection-site tenderness and, with the tesamorelin component, occasional mild fluid retention or joint stiffness are the commonest early observations. Some describe sleeping more deeply, which prescribers attribute to the growth-hormone pulse falling in the evening. Noticing nothing in this window is normal and is not a sign the course is not working.

This is the window one vial covers on a weekday schedule. Prescribers describe the early signs as subjective — skin feeling better hydrated, recovery from training feeling quicker — rather than anything visible. If baseline bloodwork was drawn, a repeat IGF-1 in this window is the one objective marker that the tesamorelin component is doing what it is described to do.

Where prescribers describe change in the abdomen it is in this window, and the reference point is the trials, where the visceral-fat measurement was taken at 26 weeks. It typically takes a second and third vial to reach, and the trials used a higher, daily dose and did not measure skin.

Skin turnover is slow, and GHK-Cu's described effects on collagen and matrix are slow by nature; prescribers who use RADIANCE with skin quality as a goal describe texture changes, where they occur, as a two-month-plus proposition. Nothing produces visible skin change in two weeks. After a course there is no withdrawal and no rebound described for GHK-Cu; for tesamorelin, the trials' safety extensions reported visceral fat returning toward baseline within months of stopping, which is the honest expectation for a medication that works only while it is being taken.

The directions are written in millilitres and in insulin-syringe units because that is what you can actually read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication. Because the two peptides are in fixed proportion, every dose delivers the same split — 2.5 mg GHK-Cu and 0.5 mg tesamorelin — and you cannot take more of one and less of the other. If your directions and syringe markings appear to disagree, ask before dosing.

Subcutaneous means into the fat layer, not the muscle. The abdomen is the usual site for this blend — the approved tesamorelin product is directed into the abdomen, rotating sites — with the thigh as an alternative if your directions allow it. Injecting into the face or another area you want to change is not how the blend is used; the mechanisms described are systemic. On timing, growth hormone is released mostly during sleep, so many prescribers direct the injection in the evening, sometimes on an empty stomach because a fatty meal blunts the pulse; others direct mornings for consistency. Your printed directions win over anything on this page.

20 doses at five per week is four weeks of weekday dosing, which is why refills run on a monthly cycle. Weekends off is part of the schedule, not a missed dose; prescribers describe the two-day break as a way of keeping the pituitary responsive to the tesamorelin pulse. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating is on the label; a multi-peptide vial is not something to keep past it.

GHK-Cu on its own is the skin component without the growth-hormone axis attached. It does not need the glucose and IGF-1 bloodwork tesamorelin brings, and it does not carry tesamorelin's contraindications. RADIANCE is the fuller formula for someone whose goals include body composition as well as skin; for skin alone, the single peptide is the more targeted prescription and a physician may reasonably prefer it.

Tesamorelin on its own is the component with the human trial evidence, prescribed for the endpoint that evidence covers: visceral fat. Prescribed alone, a physician can set its dose independently rather than accepting 0.5 mg tied to 2.5 mg of GHK-Cu. RADIANCE adds the skin and matrix component for someone who wants both; it is not a stronger tesamorelin.

The other GHK-Cu blends pair it with repair peptides rather than a secretagogue. GLOW adds BPC-157 and TB-500; KLOW adds KPV to those; the ETERNAL blend adds epithalon. None of them acts on the growth-hormone axis, none needs the bloodwork tesamorelin does, and all are aimed at tissue repair and inflammation alongside skin. RADIANCE is the GHK-Cu blend for someone whose second goal is body composition rather than a tendon, joint or gut problem.